Inhibition of brain angiotensin III attenuates sympathetic hyperactivity and cardiac dysfunction in rats post-myocardial infarction

Cardiovascular Research

Volumn 97, Issue 3, 2013, Pages 424-431

  Huang, Bing S ^a   Ahmad, Monir ^a   White, Roselyn A ^a   Marc, Yannick ^b   Llorens Cortes, Catherine ^b   Leenen, Frans H H ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b College de France ^*  (France)

Author keywords

Aminopeptidase A inhibitor; Angiotensin III; Brain; LV dysfunction; Sympathetic hyperactivity

Indexed keywords

ALDOSTERONE; ANGIOTENSIN III; CORTICOSTERONE; GLUTAMYL AMINOPEPTIDASE; PEPTIDE HYDROLASE INHIBITOR; RB 150; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; HEART HEMODYNAMICS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; IN VITRO STUDY; NERVE CONDUCTION; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC DISEASE; NONHUMAN; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC FUNCTION; SYMPATHETIC HYPERACTIVITY;

ALDOSTERONE; ANGIOTENSIN III; ANIMALS; BAROREFLEX; BLOOD PRESSURE; BRAIN; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DISULFIDES; GLUTAMYL AMINOPEPTIDASE; HEART RATE; INFUSIONS, INTRAVENTRICULAR; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; RENIN-ANGIOTENSIN SYSTEM; STROKE VOLUME; SULFONIC ACIDS; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84874236660     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvs420     Document Type: Article

References (54)

1. Ahmad M, White R, Tan J, Huang BS, Leenen FHH. Angiotensin-converting enzyme inhibitors, inhibition of brain and peripheral angiotensin-converting enzymes, and left ventricular dysfunction in rats after myocardial infarction. J Cardiovasc Pharmacol 2008;51:565-572.
2. Huang BS, Ahmad M, Tan J, Leenen FHH. Sympathetic hyperactivity and cardiac dysfunction post-MI: different impact of specific CNS versus general AT1 receptor blockade. J Mol Cell Cardiol 2007;43:479-486.
3. Wang H, Huang BS, Ganten D, Leenen FHH. Prevention of sympathetic and cardiac dysfunction after myocardial infarction in transgenic rats deficient in brain angiotensinogen. Circ Res 2004;94:843-849.
4. Zhang ZH, Francis J, Weiss RM, Felder RB. The renin-angiotensin- aldosterone system excites hypothalamic paraventricular nucleus neurons in heart failure. Am J Physiol 2002;283:H423-H433.
5. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006;48:1005-1011.
6. Wei SG, Yu Y, Zhang ZH, Weiss RM, Felder RB. Mitogen-activated protein kinases mediate upregulation of hypothalamic angiotensin II type 1 receptors in heart failure rats. Hypertension 2008;52:679-686.
7. Tan J, Wang H, Leenen FHH. Increases in brain and cardiac AT1 receptor and ACE densities after myocardial infarct in rats. Am J Physiol 2004;286:H1665-H1671.
8. Huang BS, Ahmad M, Tan J, Leenen FHH. Chronic central versus systemic blockade of AT1 receptors and cardiac dysfunction in rats post-myocardial infarction. Am J Physiol 2009;297:H968-H975.
9. Pourdjabbar A, Parker TG, Nguyen QT, Desjardins JF, Lapointe N, Tsoporis JN et al. Effects of pre-, peri-, and postmyocardial infarction treatment with losartan in rats: effect of dose on survival, ventricular arrhythmias, function, and remodeling. Am J Physiol 2005;288:H1997-H2005.
10. Jasmin JF, Calderone A, Leung TK, Villeneuve L, Dupuis J. Lung structural remodeling and pulmonary hypertension after myocardial infarction: complete reversal with irbesartan. Cardiovasc Res 2003;58:621-631.
11. Lacour C, Roccon A, Galindo G, Canals F, Hogie M, Segondy D et al. Effects of differential blockade of the renin-angiotensin system in postinfarcted rats. Fundam Clin Pharmacol 2004;18:299-307.
12. Gottlieb SS, Dickstein K, Fleck E, Kostis J, Levine TB, LeJemtel T et al. Hemodynamic and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure. Circulation 1993;88:1602-1609.
13. Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K et al. Losartan in heart failure. Hemodynamic effects and tolerability. Circulation 1995;91:691-697.
14. Lang RM, Elkayam U, Yellen LG, Krauss D, McKelvie RS, Vaughan DE et al. Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. J Am Coll Cardiol 1997;30:983-991.
15. Onodera H, Matsunaga T, Tamura Y, Maeda N, Higuma T, Sasaki S et al. Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction. Am Heart J 2005;150:689.e11-689.e16.
16. Huang BS, Leenen FHH. The brain renin-angiotensin-aldosterone system: a major mechanism for sympathetic hyperactivity and left ventricular remodeling and dysfunction after myocardial infarction. Curr Heart Fail Rep 2009;6:81-88.
17. Felder RB, Yu Y, Zhang ZH, Wei SG. Pharmacological treatment for heart failure: a view from the brain. Clin Pharmacol Ther 2009;86:216-220.
18. Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 1995;59:269-295.
19. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R et al. 'Mixed inhibitor-prodrug' as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem 1992;35:2473-24781.
20. Chauvel EN, Llorens-Cortès C, Coric P, Wilk S, Roques BP, Fournié-Zaluski MC. Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols. J Med Chem 1994;37:2950-2957.
21. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA 1996;93:11968-11973.
22. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P et al. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA 1999;96:13415-13420.
23. Wright JW, Tamura-Myers E, Wilson WJ, Roques BP, Llorens-Cortes C, Speth RC et al. Conversion of brain angiotensin II to III is critical for pressor response in rats. Am J Physiol 2003;284:R725-R733.
24. Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P et al. Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension. Proc Natl Acad Sci USA 2004;101:7775-7780.
25. Marc Y, Llorens-Cortes C. The role of the brain renin-angiotensin system in hypertension: implications for new treatment. Prog Neurobiol 2011;95:89-103.
26. Bodineau L, Frugière A, Marc Y, Inguimbert N, Fassot C, Balavoine F et al. Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension. Hypertension 2008;51:1318-1325.
27. Rozenfeld R, Iturrioz X, Maigret B, Llorens-Cortes C. Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A. J Biol Chem 2002;277: 29242-29252.
28. Huang BS, Leenen FHH. Brain 'ouabain' and angiotensin II in salt-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1996;28:1005-1012.
29. DiBona GF, Sawin LL. Renal nerve activity in conscious rats during volume expansion and depletion. Am J Physiol 1985;248:F15-F23.
30. DiBona GF, Jones SY, Brooks VL. ANG II receptor blockade and arterial baroreflex regulation of renal nerve activity in cardiac failure. Am J Physiol 1995;269: R1189-R1196.
31. Glowinski J, Iversen LL. Regional studies of catecholamines in the rat brain. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem 1966;13:655-669.
32. Nagatsu I, Nagatsu T, Yamamoto T, Glenner GG, Mehl JW. Purification of aminopeptidase A in human serum and degradation of angiotensin II by the purified enzyme. Biochim Biophys Acta 1970;198:255-270.
33. Healy DP, Wilk S. Localization of immunoreactive glutamyl aminopeptidase in rat brain. II. Distribution and correlation with angiotensin II. Brain Res 1993;606:295-303.
34. Lojda Z, Gossrau R. Study on aminopeptidase A. Histochemistry 1980;67:267-290.
35. Zini S, Masdehors P, Lenkei Z, Fournie-Zaluski MC, Roques BP, Corvol P et al. Aminopeptidase A distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience 1997;78:1187-1193.
36. de Mota N, Iturrioz X, Claperon C, Bodineau L, Fassot C, Roques BP et al. Human brain aminopeptidase A: biochemical properties and distribution in brain nuclei. J Neurochem 2008;106:416-428.
37. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci 2006;7: 335-346.
38. Song L, Healy DP. Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. Hypertension 1999;33:746-752.
39. Meng QC, Durand J, Chen YF, Oparil S. Effects of dietary salt on angiotensin peptides in kidney. J Am Soc Nephrol 1995;6:1209-1215.
40. Healy DP, Song L. Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. Hypertension 1999;33:740-745.
41. Yu Y,Wei SG, Zhang ZH, Gomez-Sanchez E,Weiss RM, Felder RB. Does aldosterone upregulate the brain renin-angiotensin system in rats with heart failure? Hypertension 2008;51:727-733.
42. Reudelhuber TL. The renin-angiotensin system: peptides and enzymes beyond angiotensin II. Curr Opin Nephrol Hypertens 2005;14:155-159.
43. Chappell MC. Emerging evidence for a functional angiotensin-converting enzyme 2-angiotensin-(1-7)-MAS receptor axis: more than regulation of blood pressure? Hypertension 2007;50:596-599.
44. Isa K, Arnold AC, Westwood BM, Chappell MC, Diz DI. Angiotensin- converting enzyme inhibition, but not AT(1) receptor blockade, in the solitary tract nucleus improves baroreflex sensitivity in anesthetized transgenic hypertensive (mRen2)27 rats. Hypertens Res 2011;34:1257-1262.
45. Feng Y, Xia H, Cai Y, Halabi CM, Becker LK, Santos RA et al. Brain-selective overexpression of human Angiotensin-converting enzyme type 2 attenuates neurogenic hypertension. Circ Res 2010;106:373-382.
46. Sriramula S, Cardinale JP, Lazartigues E, Francis J. ACE2 overexpression in the paraventricular nucleus attenuates angiotensin II-induced hypertension. Cardiovasc Res 2011;92:401-408.
47. Leenen FHH, Skarda V, Yuan B, White R. Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors. Am J Physiol 1999;276: H317-H325.
48. Vahid-Ansari F, Leenen FHH. Pattern of neuronal activation in rats with CHF after myocardial infarction. Am J Physiol 1998;275:H2140-H2146.
49. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in the central nervous system activation and sympathoexcitation of myocardial infarction-induced heart failure. Circ Res 2004;94:402-409.
50. Huang BS, Ahmadi S, Ahmad M, White RA, Leenen FHH. Central neuronal activation and pressor responses induced by circulating ANG II: role of the brain aldosterone-'ouabain' pathway. Am J Physiol 2010;299:H422-H430.
51. Huang BS, Leenen FHH. Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI. Am J Physiol 2005;288:H2491-H2497.
52. Huang BS, White RA, Ahmad M, Tan J, Jeng AY, Leenen FHH. Central infusion of aldosterone synthase inhibitor attenuates left ventricular dysfunction and remodeling in rats after myocardial infarction. Cardiovasc Res 2009;81:574-781.
53. Francis J,Weiss RM,Wei SG, Johnson AK, Beltz TG, Zimmerman K et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol 2001;281:H2241-H2251.
54. Marc Y, Gao J, Balavoine F, Michaud A, Roques BP, Llorens-Cortes C. Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats. Hypertension 2012;60:411-418.